News

Meet Med Discovery at BIO 2010.
2010-04-23, Med Discovery will be part of the Swiss presence at the Biotechnology Industry Organization’s annual International Convention in Chicago, May 3-6th..
Read more

Med Discovery out-licenses dermatology rights of kallikrein inhibitor
2010-03-01, Med Discovery has out-licensed all dermatology rights of its lead inhibitor to Dermadis SA..
Read more

Orphan drug designation of MDPK67b for Netherton syndrome approved
2009-11-27, Med Discovery has received a positive opinion from the EMEA on orphan medicinal product status for MDPK67b for the dermatology disorder Netherton Syndrome.
Read more

CTI awards grant for chemotherapy induced neutropenia research
2009-10-16, The University of Zürich and Med Discovery have received a grant from the CTI (Swiss federal agency for the promotion of innovation) to support their collaborative research on the use of protease inhibitors in chemotherapy induced neutropenia..
Read more

Med Discovery appoints Jean De Serres to Board of Directors
2009-10-09, Jean De Serres VP of Draximage (Kirkland, QC, Canada) joins the Board of Directors of Med Discovery.
Read more

Med Discovery participates in successful ISK 2009 conference
2009-09-04, Med Discovery was major sponsor and presenter at the 3rd International Symposium on Kallikreins and Kallikrein-related Peptidases in Munich .
Read more

Med Discovery in-licenses RasGAP chemotherapy enhancer technology
2009-06-16, Med Discovery has signed an in-licensing deal with the University of Lausanne for its RasGAP-derived chemotherapy enhancing peptide technology.
Read more

Meet Med Discovery at BIO Atlanta
2009-05-04, Med Discovery will be at the BIO conference 18-21 May 2009 in Atlanta.
Read more